Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors
Nov 27
Have your own idea? Try our Stock Screener
Chinese (SSE) Biotech Industry Analysis
UpdatedDec 22, 2024
DataAggregated Company Financials
Companies72
- 7D-1.9%
- 3M22.5%
- 1Y-16.2%
- YTD-19.1%
Over the last 7 days, the Biotech industry has dropped 1.9%, and Shanghai RAAS Blood Products contributed the most with a 3.7% decline. The industry has fallen 16% in the last year. As for the next few years, earnings are expected to grow by 44% per annum.
Industry Valuation and Performance
Has the Chinese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 22 Dec 2024 | CN¥871.6b | CN¥136.0b | CN¥10.8b | 33.9x | 81x | 6.4x |
| Tue, 19 Nov 2024 | CN¥902.5b | CN¥141.7b | CN¥11.2b | 36.4x | 80.6x | 6.4x |
| Thu, 17 Oct 2024 | CN¥869.1b | CN¥154.1b | CN¥14.5b | 36.9x | 60.1x | 5.6x |
| Sat, 14 Sep 2024 | CN¥737.3b | CN¥154.1b | CN¥14.5b | 31x | 50.8x | 4.8x |
| Mon, 12 Aug 2024 | CN¥819.5b | CN¥161.2b | CN¥17.3b | 30.7x | 47.4x | 5.1x |
| Wed, 10 Jul 2024 | CN¥806.4b | CN¥161.1b | CN¥17.3b | 31.2x | 46.6x | 5x |
| Fri, 07 Jun 2024 | CN¥879.1b | CN¥161.1b | CN¥17.3b | 31.6x | 50.8x | 5.5x |
| Sun, 05 May 2024 | CN¥950.2b | CN¥161.1b | CN¥17.3b | 34.8x | 55x | 5.9x |
| Tue, 02 Apr 2024 | CN¥987.7b | CN¥161.0b | CN¥20.1b | 40.5x | 49.1x | 6.1x |
| Thu, 29 Feb 2024 | CN¥985.0b | CN¥168.6b | CN¥21.4b | 35x | 46x | 5.8x |
| Sat, 27 Jan 2024 | CN¥964.3b | CN¥167.9b | CN¥21.4b | 35.1x | 45x | 5.7x |
| Mon, 25 Dec 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 39.4x | 50x | 6.4x |
| Wed, 22 Nov 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 42.1x | 52.6x | 6.7x |
| Fri, 20 Oct 2023 | CN¥1.0t | CN¥170.9b | CN¥25.2b | 40.6x | 41.2x | 6.1x |
| Sun, 17 Sep 2023 | CN¥1.0t | CN¥170.9b | CN¥25.2b | 39.5x | 41x | 6x |
| Tue, 15 Aug 2023 | CN¥1.0t | CN¥173.8b | CN¥28.2b | 38.3x | 37.1x | 6x |
| Thu, 13 Jul 2023 | CN¥1.1t | CN¥177.4b | CN¥29.3b | 39.4x | 36.4x | 6x |
| Sat, 10 Jun 2023 | CN¥1.1t | CN¥177.3b | CN¥29.3b | 39x | 36.9x | 6.1x |
| Mon, 08 May 2023 | CN¥1.2t | CN¥177.5b | CN¥29.5b | 42.9x | 40.2x | 6.7x |
| Wed, 05 Apr 2023 | CN¥1.2t | CN¥186.0b | CN¥36.6b | 40x | 33.7x | 6.6x |
| Fri, 03 Mar 2023 | CN¥1.3t | CN¥178.9b | CN¥36.0b | 42.7x | 35.4x | 7.1x |
| Sun, 29 Jan 2023 | CN¥1.3t | CN¥179.6b | CN¥38.0b | 44x | 35.2x | 7.4x |
| Tue, 27 Dec 2022 | CN¥1.2t | CN¥175.6b | CN¥37.9b | 38x | 31.5x | 6.8x |
| Thu, 24 Nov 2022 | CN¥1.2t | CN¥175.5b | CN¥37.9b | 39.3x | 32.5x | 7x |
| Sat, 22 Oct 2022 | CN¥1.2t | CN¥175.6b | CN¥41.1b | 34.7x | 29.1x | 6.8x |
| Mon, 19 Sep 2022 | CN¥1.2t | CN¥174.0b | CN¥40.1b | 31.2x | 28.9x | 6.7x |
| Wed, 17 Aug 2022 | CN¥1.3t | CN¥171.9b | CN¥43.3b | 36.1x | 29x | 7.3x |
| Fri, 15 Jul 2022 | CN¥1.3t | CN¥168.1b | CN¥42.4b | 37.3x | 30.6x | 7.7x |
| Sun, 12 Jun 2022 | CN¥1.2t | CN¥168.1b | CN¥42.4b | 36.3x | 28.7x | 7.2x |
| Tue, 10 May 2022 | CN¥1.2t | CN¥168.1b | CN¥42.4b | 35.7x | 28.6x | 7.2x |
| Thu, 07 Apr 2022 | CN¥1.5t | CN¥153.1b | CN¥40.8b | 43.6x | 35.8x | 9.5x |
| Sat, 05 Mar 2022 | CN¥1.4t | CN¥152.0b | CN¥40.7b | 48x | 35.3x | 9.4x |
| Mon, 31 Jan 2022 | CN¥1.4t | CN¥143.8b | CN¥38.7b | 43.1x | 35x | 9.4x |
| Wed, 29 Dec 2021 | CN¥1.5t | CN¥141.8b | CN¥38.5b | 49x | 39.9x | 10.8x |
Price to Earnings Ratio
39.9x
Current Industry PE
- Investors are optimistic on the Chinese Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 81.0x which is higher than its 3-year average PE of 41.9x.
- The industry is trading close to its 3-year average PS ratio of 6.8x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 35% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | -1.18% | |
| Healthcare | -2.08% | |
| Biotech | -1.89% | |
| Biotech | -1.89% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 002007 Hualan Biological Engineering | CN¥17.82 | 4.6% +CN¥1.4b | -18.7% | PE24.4x | |
| 688278 Xiamen Amoytop Biotech | CN¥70.91 | 4.5% +CN¥1.3b | 37.9% | PE38.9x | |
| 603392 Beijing Wantai Biological Pharmacy Enterprise | CN¥76.30 | 1.2% +CN¥1.2b | 18.2% | PS38.8x | |
| 600645 Vcanbio Cell & Gene Engineering | CN¥21.53 | 7.7% +CN¥702.1m | 10.1% | PE91.3x | |
| 688136 Kexing Biopharm | CN¥20.59 | 15.0% +CN¥530.8m | 5.7% | PS3.1x |
